Katrin Hoffmann

Katrin Hoffmann is an accomplished leader in the pharmaceutical industry with extensive experience in rare diseases and commercial strategy. Currently serving as the Global Asset Head for Rare Epilepsies at UCB since November 2016, Katrin has held multiple key positions, including Head of Rare Disease Launch and Operational Excellence and Head of Early Evidence Strategy, where a patient-centered and evidence-based approach was emphasized. Katrin's prior experience at Shire included roles as Global Commercial Insights and Analytics Team Lead, where guidance on brand strategy and team leadership was pivotal. Earlier career episodes at ZS Associates provided foundational consulting experience in various analytical roles. Katrin holds a Master's degree in Psychology and Business Administration from the University of Mannheim, along with specialized training in Health Economics.